78784-70-0

Basic information

• Product Name: 3-CHLORO-6-(2-PYRIDINYLMETHYL)PYRIDAZINE
• Synonyms: 3-chloro-6-(pyridin-2-yl)pyridazine;3-Chloro-6-(2-pyridinyl)pyridazine
• CAS NO: 78784-70-0
• Molecular Formula: C₉H₆ClN₃
• Molecular Weight: 191.62
• Mol File: 78784-70-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 378°C at 760 mmHg
• Flash Point: 214.2°C
• Appearance: /
• Density: 1.281g/cm³
• Vapor Pressure: 1.41E-05mmHg at 25°C
• Refractive Index: 1.597
• CAS DataBase Reference: 3-CHLORO-6-(2-PYRIDINYLMETHYL)PYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-6-(2-PYRIDINYLMETHYL)PYRIDAZINE(78784-70-0)
• EPA Substance Registry System: 3-CHLORO-6-(2-PYRIDINYLMETHYL)PYRIDAZINE(78784-70-0)

Safety Data

• Hazardous Substances Data: 78784-70-0(Hazardous Substances Data)

Usage

Description

3-Chloro-6-(2-pyridinylmethyl)pyridazine, also known as Bifeprunox, is a pyridazine derivative with the molecular formula C12H9ClN4. It acts as a dopamine receptor partial agonist and exhibits serotonin receptor agonist and antagonist activity. Bifeprunox has been studied for its potential use as an antipsychotic and antidepressant medication, showing efficacy in treating schizophrenia and bipolar disorder in clinical trials. Its unique pharmacological profile makes it a promising compound for the treatment of various psychiatric disorders, although more research is needed to fully understand its mechanism of action and potential therapeutic uses.

Uses

Used in Pharmaceutical Industry:
3-Chloro-6-(2-pyridinylmethyl)pyridazine is used as an antipsychotic and antidepressant medication for the treatment of psychiatric disorders such as schizophrenia and bipolar disorder. Its unique pharmacological profile, which includes dopamine receptor partial agonism and serotonin receptor agonist and antagonist activity, contributes to its efficacy in managing these conditions.
Used in Research and Development:
3-Chloro-6-(2-pyridinylmethyl)pyridazine is used in research and development for the study of its potential therapeutic uses and mechanism of action. Further investigation is needed to fully understand its role in treating various psychiatric disorders and to explore additional applications in the field of mental health.

InChI:InChI=1/C10H8ClN3/c11-10-5-4-9(13-14-10)7-8-3-1-2-6-12-8/h1-6H,7H2

Upstream product

• 160427-24-7 4-Hydroxy-6-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one 
• 1005036-22-5 potassium 2-hydroxy-4-oxo-4-(pyridin-2-yl)butanoate 
• 1122-62-9 2-acetylpyridine 
• 109-04-6 2-bromo-pyridine 
• 135034-10-5 3-chloro-6-iodopyridazine 
• 66317-38-2 6-(pyridine-2-yl)-2,3-dihydropyridazin-3-one 

Downstream Products

• 479628-50-7 3-(pyridin-2-yl)pyridazine 
• 1005035-89-1 6-(pyridin-2-yl)-3-(tributylstannyl)-pyridazine 
• 1005035-91-5 C₁₃H₁₅N₃ 
• 1177267-50-3 (trans)-8-({[6-(2-fluorophenyl)-3-pyridazinyl]amino}methyl)-3-(2-fluoro-3-pyridinyl)-1-oxa-3-azaspiro[4.5]decan-2-one 

Relevant articles and documents

Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses

The present invention relates to nonlinear oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to oligopyrroles and to the uses of the pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the uses in the materials, environmental, electronics and optics field.

HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.